Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo

All NewsApril 13, 2026

Revolution Medicines stock rises after Phase 3 daraxonrasib data show survival gains in pancreatic cancer, with regulatory filings planned.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent